Blood sample volumes in child health research: review of safe limits

Howie, Stephen R. C.

doi:10.2471/blt.10.080010

Cited by 222 publications

(201 citation statements)

References 9 publications

Supporting

Mentioning

191

Contrasting

Order By: Relevance

“…With the BCS requiring 130 μL of plasma, a typical neonate whole blood only consists of 32–45% plasma28 it would require approximately 300–400 μL of neonate whole blood per test, while the Thrombinoscope would require approximately 175–250 μL of neonate whole blood and approximately 90–125 μL neonate whole blood per test for the Technothrombin system. With a 1 kg neonate, the maximum daily limit of blood withdrawal is between 1 and 4 mL depending on guidelines,29 which greatly restricts the number of test that can be performed, especially when a typical thrombogram is run in triplicate.…”

Section: Thrombin Generation In Clincal Setttingsmentioning

confidence: 99%

A review of commercially available thrombin generation assays

Kintigh

Monagle

Ignjatović

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Essentials Overview of the three commercial thrombin generation methods.Description of the sample preparation, data management, and analysis.Description of the similarities and differences in regards to substrates results.Discussion of advantages and disadvantages of the three approaches. Currently there are three commercially available thrombin generation methods. These methods help detect the levels of thrombin generated in patient samples by the use of chromogenic or fluorogenic substrates in plasma or whole blood. Determining the rate of thrombin generation can help indicate if patients are at risk of clotting or bleeding. This review discusses two fluorogenic and one chromogenic method and focuses on similarities and differences of these three methods. The review specifically focuses on the accuracy of commercial substrates used in thrombin generation, and interference that can occur by various plasma proteins, as well as on evaluating the advantages and disadvantages of each method. The commercial chromogenic assay and both fluorogenic assays are able to monitor the rate of thrombin generation and can give indications towards potential coagulation abnormalities. Overall, the main differences between the thrombin generation methods are based on the type of substrate used, sample preparation, and data processing. Despite advancement in this field there are still technical challenges that preclude the widespread use of thrombin generation in clinical applications.

show abstract

Section: Thrombin Generation In Clincal Setttingsmentioning

confidence: 99%

A review of commercially available thrombin generation assays

Kintigh

Monagle

Ignjatović

2018

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…In infants, < 5 % of the total blood volume should be removed in a single draw, but several blood draws per day may be requested in acutely ill inpatients [21,25] . The most suitable mean to reduce the risk of iatrogenic anemia and transfusion is obviously the reduction of sample volume.…”

Section: Pediatric Blood Collectionmentioning

confidence: 99%

Preanalytical quality improvement: in quality we trust

Lippi

Becan-McBride

Behúlová

et al. 2012

Clinical Chemistry and Laboratory Medicine (CCLM)

189

123

View full text Add to dashboard Cite

Total quality in laboratory medicine should be defined as the guarantee that each activity throughout the total testing process is correctly performed, providing valuable medical decision-making and effective patient care. In the past decades, a 10-fold reduction in the analytical error rate has been achieved thanks to improvements in both reliability and standardization of analytical techniques, reagents, and instrumentation. Notable advances in information technology, quality control and quality assurance methods have also assured a valuable contribution for reducing diagnostic errors. Nevertheless, several lines of evidence still suggest that most errors in laboratory diagnostics fall outside the analytical phase, and the pre-and postanalytical steps have been found to be much more vulnerable. This collective paper, which is the logical continuum of the former already published in this journal 2 years ago, provides additional contribution to risk management in the preanalytical phase and is a synopsis of the lectures of the 2nd European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)-Becton Dickinson (BD) European Conference on Preanalytical Phase meeting entitled " Preanalytical quality improvement: in quality we trust " (Zagreb, Croatia, 1 -2 March 2013). The leading topics that will be discussed include quality indicators for preanalytical phase, phlebotomy practices for collection of blood gas analysis and pediatric samples, lipemia and blood collection tube interferences, preanalytical requirements of urinalysis, molecular biology hemostasis and platelet testing, as well as indications on best practices for safe blood collection. Auditing of the preanalytical phase by ISO assessors and external quality assessment for preanalytical phase are also discussed.

show abstract

“…This problem is often heightened when a study requires the collection of samples into several tubes, which can be met with significant resistance because of the perception that this implies that more blood is being collected. 23 A clear explanation of what blood samples in different tubes are to be used for is usually helpful in allaying anxiety. In other regions, there is the belief that if a child received oral polio vaccines, the child could become sterile and may be infected with human immunodeficiency virus.…”

Section: Impact Of Clinical Trials On the Communitymentioning

confidence: 99%

Impact, Challenges, and Future Projections of Vaccine Trials in Africa

Idoko

Kochhar²,

Agbenyega³

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Immunization remains the most cost effective method for the control of infectious diseases. Therefore, there is a global effort to deploy new vaccines for disease control and eradication. These new vaccines must be tested in the settings in which they will be used. This necessity has required the conduct of many vaccine trials in Africa, where several infectious diseases with significant public health impact are prevalent. However, these areas have peculiarities and are just beginning to gain expertise in the conduct of such trials. The vaccine developers and sponsors of these trials may also not be conversant with some issues unique to the trial site. The understanding gap from both partners can result in challenges if not addressed during the planning phase of the trial. This review seeks to highlight the issues surrounding the conduct of clinical trials in resource-constrained settings and suggests some ways of circumventing them.

show abstract

Blood sample volumes in child health research: review of safe limits

Cited by 222 publications

References 9 publications

A review of commercially available thrombin generation assays

A review of commercially available thrombin generation assays

Preanalytical quality improvement: in quality we trust

Impact, Challenges, and Future Projections of Vaccine Trials in Africa

Contact Info

Product

Resources

About